The research and development for antimicrobial agents in the post genome age

• Published in: Japanese Journal of Chemotherapy Vol. 52; no. 7; pp. 347 - 354
• Main Author: Sasaki, Shimaru
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 2004; 公益社団法人 日本化学療法学会
• Subjects: genomic novel drug discovery; peptide deformylase inhibitor; quinolone; β-lactum
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.52.347

The history of developing in discovery of antimicrobial agents in Japan started with the chemical studies and in vitro studies at first and then transited with the studies by genomic researches. The antimicrobial agents used clinically in Japan consist from β-lactam type, quinolone type, macrolide type, aminoglucoside type, glycopeptide type, streptogramin type, oxazolidinone type, and others. Among these type of antimicrobial agent, the drugs in which the developing in drug discovery continues still are mainly oral and injectable cephems, oral and injectable carbapenems, oral and injectable quinolones and ketolides. In drug discovery by genomic researches, the essential genes for bacterial living are regarded as the target of drug discovery. In order to find the examples for the target of drug discovery by genomic research, we searched the reports in Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held on 2002 and 2003. Among these reports, we could found many inhibitors of various steps that are essential for bacterial living. As the typical inhibitor, the peptide deformylase inhibitor (PDF) was observed and the exclusive session for PDF could be found.